Document is current
Any future updates will be listed below
-
Authors
Weise, Gunnar https://orcid.org/0009-0006-4546-7650
Rautenberg, Christina https://orcid.org/0000-0002-0611-1372
Denk, Alexander
Massoud, Radwan https://orcid.org/0000-0001-9275-3840
Meedt, Elisabeth
Wolff, Daniel https://orcid.org/0000-0001-7015-3190
Schroeder, Thomas
Ayuk, Francis https://orcid.org/0000-0001-6297-1847
-
Funding
Funding for this research was provided by:
Jazz Pharmaceuticals
AbbVie
Servier
financial travel support from Medac, BMS Celgene
Novartis | Novartis Pharma
Therakos
honoraria from Incyte, Sanofi, Neovii and Behring.
- License Information
-
More Information
Article History
Received: 15 September 2025
Revised: 4 November 2025
Accepted: 19 November 2025
First Online: 16 December 2025
Competing interests
: D.W. received a research grant from Novartis and honoraria from Novartis, Incyte, Sanofi, Therakos, Neovi and Behring. C.R. received a research grant from Jazz Pharmaceuticals; lecture fees and advisory boards with honoraria from Jazz Pharmaceuticals, AbbVie, Servier; financial travel support from Jazz Pharmaceuticals, AbbVie, Medac, BMS Celgene.
: This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (protocol code: 2022-100964-BO-ff; date of approval: 30 January 2023). Informed consent is not necessary for this retrospective study in accordance with ยง 12 of Hamburg Hospital law.
